Sun Pharma gets USFDA nod for Prometh syrup

Drug major Sun Pharma has received approval from the US health regulator for generic version of anti-allergic product Prometh syrup. The United States Food and Drug Administration (FDA) has granted an approval to the company's subsidiary for the syrup.

The company's product--Promethazine Hydrochloride and Codeine Phosphate Oral Syrup--is bioequivalent to Prometh. It has annual sales of about $16 million in the US. The medicine is used to treat symptoms caused by common cold, flu, allergies or other breathing problems.